Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rep. Pallone Introduces DSHEA Implementation Companion Bill

This article was originally published in The Tan Sheet

Executive Summary

The "Dietary Supplement Regulatory Implementation Act of 2004" would establish a system detailing "requirements" for reporting serious adverse events associated with supplement use
Advertisement

Related Content

Future DSHEA Challengers Will Learn From McCain Bill Failure - NPA
Future DSHEA Challengers Will Learn From McCain Bill Failure - NPA
Future DSHEA Challengers Will Learn From McCain Bill Failure - NPA
Appropriations for DSHEA
House Bills Aim To Loosen Health Claims Regs, Fully Fund DSHEA
Supplement Coverage Under HSAs, FSAs Called For In Proposed Legislation
Lewin Study Shows Calcium, Folic Acid Use Could Result In $15 Bil. Savings
Senators Durbin, Hatch To Work Together On AER Plan
Senators Durbin, Hatch To Work Together On AER Plan
DSHEA Implementation Action Expected In Second Session Of 108th Congress

Topics

Advertisement
UsernamePublicRestriction

Register

PS097024

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel